We aimed to determine somatic mutational profiles of stage II/III gastric cancers (GCs) according to their tumor microenvironment immune types (TMITs), which classify cancer based on co- mutations were more frequently found in TMIT II. TMIT III had a unique somatic mutation profile harboring enriched mutations of histone modifiers including CREBBP and KMT2A, and we found FGFR2 amplification exclusively within TMIT IV. Fuzzy clustering analysis based on somatic mutation frequencies identified a hypermutated group (cluster 1) and a hypomutated group (cluster 2). Cluster 1 had significant associations with TMIT I, EBV + GCs, and MSI-H GCs (P = .023, .014, and .004), and had better overall survival (P = .057) than Cluster 2. TMIT I, EBV + , and MSI-H GCs were estimated to have greater tumor mutational burden (P = .023, .003, and .015). By analyzing somatic mutation profiles according to TMIT classification, we identified TMIT-specific genetic alterations that provide clues for biological linkage between GC genetics and microenvironment.
| INTRODUCTION
Gastric cancer (GC) is one of the most common causes of cancerrelated deaths worldwide, 1 despite considerable advances in therapeutics such as targeted biological agents, including trastuzumab. 2 Following the success of immunotherapy in the treatment of many types of solid tumors 3, 4 and considering the relatively high burden of somatic mutations in GCs, 5 there has been a growing interest in GC as a target for immunotherapy. In fact, recent clinical trials of pembrolizumab and nivolumab, the anti-PD-1 antibodies, have demonstrated their promising activity of immunotherapeutic agent in GCs. [6] [7] [8] The classification of tumor microenvironment immune type (TMIT) was originally developed for a more tangible understanding of tumor microenvironments (TMEs), thereby facilitating prediction of suitable candidates for immunotherapy. 9 TMIT classifies tumors into four . Practical application of TMIT classification in RNAseq data of 32 types of solid tumors has confirmed that TMIT I is associated with a higher mutational burden and oncogenic viral infection. 10 In addition, in our previous study, we applied TMIT classification for human GC tissue samples and showed the close relationship between TMIT I and two distinct types of GCs-Epstein-Barr Virus + (EBV + ) and microsatellite instability high (MSI-H) GCs-suggesting that a close association exists between TME and the molecular genetic characteristics of GCs. 11 Considering these molecular genetic implications of the TMIT classification in GCs, it would be necessary to identify additional genetic characteristics that might show close association with the TMIT classification, such as the somatic mutation landscape of GCs.
The main purpose of this study was to assess the somatic mutation profiles of stage II and III GCs by deep targeted sequencing. Specifically, we aimed to (i) determine significant genetic alterations specific to each TMIT, (ii) evaluate EBV and MSI-H GC-specific genetic alterations, and (iii) develop a novel cluster model of stage II/III GCs solely based on somatic mutation profiles.
| MATERIALS AND METHODS

| Characterization of patients and sample acquisition
The 
| Sequence alignment and variant calling
The adapter sequences found in the raw sequencing reads were removed by cuadapt. 12 Trimmed reads were aligned to the reference genome (GRCh37/hg19) using Burrows-Wheeler Aligner-MEM (BWA-MEM). 13 Poorly mapped reads that had a mapping quality (MAPQ) below 20 were removed using Samtools version 1. 
| Variant analysis
Since matched germline samples were not available, we made efforts to reduce the effect of false-positive variants and germline contamination. The following criteria were used to filter out the less significant variants and narrow down to the clinically relevant variants: 
| Copy number variation analysis
We performed copy number variation (CNV) analysis using targeted sequencing data through in-house developed methods adapted and modified from CNVkit package. 20 To reduce the confounding effect of stromal or normal cells, tumor purity data estimated by microscopic examination were combined into analytic pipeline. CNV data were exported as log2 ratio values and we defined log2 ratio ≥ 8.0 as gene amplification.
| Tumor mutational burden
Tumor mutational burden (TMB) was calculated as the number of non-synonymous variants within interrogated panel, using in-house developed pipeline (Macrogen Inc., Seoul, Republic of Korea) adapted from previously reported methods. 21, 22 Germline mutations were filtered using dbSNP Build150, ExAC r0.3.1 (≥2 counts), ESP6500 dataset of dbNSFP v3.5a (≥2 counts), except for the variants found more than twice in COSMIC v82. To exclude false-positive variant calls, variants with AF less than 0.5% were discarded.
| EBV in situ hybridization
To assess the EBV status of individual cases, we performed EBV in situ hybridization (ISH) using INFORM EBV-encoded RNA (EBER)
probe (Ventana Medical Systems, Tucson, AZ, USA). Cases with a diffuse strong nuclear positivity were interpreted as EBV + GCs
| Microsatellite instability testing
The MSI status of the patients was assessed by comparing the allele profiles of five markers (BAT-26, BAT-25, D5S346, D17S250, and S2S123) in tumor cells to those in the matched normal samples.
Hematoxylin-eosin-stained slides were reviewed to select appropriate areas with sufficient tumor cellularity and adequate non-neoplastic gastric mucosa for macro dissection, and subsequently DNA extraction was performed. PCR amplification of the extracted DNA was carried out and the PCR products were analyzed using a DNA autosequencer (ABI 3731 Genetic Analyzer; Applied Biosystems, Foster City, CA). According to the Revised Bethesda Guidelines, tumors with additional alleles in two or more markers were classified as MSI-H, tumors with novel bands in one marker were defined as MSI-low (MSI-L), and those with identical bands in all five markers were classified as microsatellite stable (MSS). 23 
| Statistical analyses
Fisher's exact tests were used to assess significant differences in the distribution of a certain somatic mutation among the TMIT classes.
Kruskal-Wallis tests were used to assess significant differences in the numbers of variants and total mutational burden. In addition, fuzzy clustering analysis was performed to organize the sequencing data into groups harboring similar somatic mutation profiles. The KaplanMeier survival curve and log-rank test were used for survival analysis.
Most of the statistical analyses were performed using SPSS statistics 22.0 (IBM, Armonk, NY), and the fuzzy clustering analysis and data presentation were performed using the R statistical package 3.4.2
(http://www.r-project.org).
3 | RESULTS
| Somatic mutational profile of stage II and III GC patients
Among the 80 stage II/III patients selected for sequencing, 24 were classified as TMIT I, 25 as TMIT II, 6 as TMIT III, and 25 as TMIT IV. The clinicopathological characteristics of the four TMIT types are shown in Table 1 .
A total of 1503 somatic mutations in 146 cancer-related genes were reported ( Figure 1 ; Supporting Information Table S3 
| Differences in mutation profiles and gene copy number according to TMITs
The total number of somatic mutations in each TMIT varied, with TMIT I carrying the most, 435 mutations in 125 genes, followed by When compared to other TMITs, TMIT III showed a more distinct somatic mutation profile. For instance, TMIT III cases were more significantly enriched with mutations of genes encoding histone modifiers, including CREBBP (66.7%; III vs. II, P = .043) and KMT2A (66.7%; III vs. II, P = .026). In addition, well-known oncogenes, including MTOR (50%; III vs. II, P = .016) and MET (50%; III vs. II, P = .004; III vs. IV, P = .016) showed more frequent mutations in the TMIT III group.
Mutations in BRCA2 (28%) and FLT4 (24%) were significantly more common in TMIT IV patients than in TMIT II patients (P = .049
and .022, respectively).
Regarding CNV we focused on the gene amplification pattern across the four TMITs; cases with amplification in more than one gene were selected and sorted according to TMITs as in Supporting Information Figure S2 . Amplifications of genes involved in cell cycle regulation including CCNE1, CCND1, and MDM2 amplifications were observed across more than one group of TMITs.
Genes including ERBB2 and JAK2-encoding receptor tyrosine kinase and non-receptor tyrosine kinase respectively-showed amplifications within TMIT I. IGF2 amplification in TMIT II and exclusive FGFR2 amplification within TMIT IV were also notable. 
| Differences in mutation profiles based on EBV and microsatellite instability status
Among the 80 patients with stage II and III GC who were selected for deep targeted sequencing, 13 were EBV + GCs and were all in the TMIT I group. Seven MSI-H GC samples were also sequenced, and four of them were TMIT I, two were TMIT II patients, and the remaining one was TMIT III. EBV + GC patients had mutations in 11 genes (median; range, 3-57), and MSI-H GC patients had mutations in 23 genes (median; range, 2-39), thereby implying significantly higher mutation frequencies in cancer-related genes among MSI-H cases (P = .044) (Figure 3 ).
PIK3CA was one of the most commonly mutated genes in both EBV + GCs (53.8%) and MSI-H GCs (57.1%). In addition, CREBBP FIGURE 1 Somatic mutation landscape of stage II and III gastric cancer cohort. Among the 170 cancer-related genes, SNVs and indels were found in 146 genes. Previously well studied genes including TP53 and PIK3CA, as well as genes such as CREBBP, MED12, RUNX1, FLT4, and BRD4 which were less reported previously were identified as recurrently mutated genes in GCs TP53 mutation is one of the most commonly observed genetic alterations in GCs. However, none of the MSI-H GC patients in the study cohort had the TP53 mutation, while four of the 13 EBV + GC cases (30.8%) had TP53 mutations, including Y220C, R175H, L111fs, and T125T splice site variants. Other genes, which had enriched somatic mutations in MSI-H GCs compared to EBV + GCs, include ATR (86% vs. 0%, P = .017) and ASXL1 (57% vs. 0%, P = .031).
Of the five cases with RNF43 mutations among the 80 stage II/III GC cases, two had MSI-H (P = .111). POLE mutations were found in 11 cases in the present cohort, and two and three of them were EBV + and MSI-H GCs, respectively.
| Clustering analysis based on the somatic mutation profiles
Fuzzy clustering analysis was performed to suggest a novel classification of stage II and III GCs based on their somatic mutation profiles ( Figure 4A ). From the results, two distinct clusters were identified:
30 cases were classified into cluster 1 (37.5%) and 50 into cluster 2 (62.5%). Most notably, cluster 1 was composed of GCs with a significantly higher number of genetic alterations (P < .001). While cluster 1 GCs had 20 mutated genes per case (median; range, 4-57), cluster 2 GCs had 5.5 mutated genes per case (median; range, 1-25). When the clinicopathological features were compared (Table 2) , TMIT I cases showed a predilection toward cluster 1 (P = .023), and EBV positivity was significantly associated with cluster 1 (P = .014). In addition, all of the seven MSI-H GCs were categorized into cluster 1 (P = .004),
implying that mutation frequencies are higher in TMIT I, EBV + , and
MSI-H GCs. Otherwise, none of the other clinicopathological features showed significant differences between the two clusters. vs. 33.3%, P = .485).
To assess the prognostic significance of the cluster model,
Kaplan-Meier survival analysis was performed and cluster 2 showed worse overall survival (OS) compared to that of cluster 1 (P = .057) with borderline statistical significance ( Figure 4B ). 
| Tumor mutational burden
| DISCUSSION
In summary, similar somatic mutation landscapes were reported for the stage II/III GC cohort compared to The Cancer Genome Atlas (TCGA) report. 24 Though the clinicopathologic characteristics of this study population-which was selected from the previously reported larger GC cohort for additional genetic study-showed some significant differences when compared to TCGA cohort (Supporting Information Table S4 ), overall mutational distribution and frequencies were still consistent. TP53 and PIK3CA, the most commonly mutated genes according to the TCGA report, were mutated at frequencies of 38.8%
and 25.0% in this study and ranked high among the recurrently mutated genes. The mutations of genes involved in the Wnt signaling pathway (GNAQ, CREBBP, CDH1, APC, CTNNB1, and RNF43) and the TGF-β pathway (SMAD4 and SMAD2) were observed to be at similar mutation frequencies in the present cohort when compared to that mentioned in the TCGA report.
The somatic mutation signatures of GCs according to the TMIT classification were determined for understanding tumor genetics showed that FGFR3 mutations are found in about 1.2% of GCs. 25 Though there is a discrepancy between alleged FGFR3 mutation frequencies with those seen in the current study, recent attention toward FGFR targeted therapy 26 suggests that the enrichment of
FGFR3 mutations within TMIT II may have clinical implications. RUNX1
(runt related transcription factor 1) is a tumor suppressor gene studied mostly in hematolymphoid diseases. It has been reported that 15% of esophageal tumors, also a gastrointestinal malignancy, have deletions in RUNX1. 27 More recently, it has been reported that microRNA216a-3p (miR-216a-3p) downregulates RUNX1 in GCs and activates the NF-κB signaling pathway, 28 implying the potential role of RUNX1 gene in GC carcinogenesis.
TMIT III was the smallest subgroup among stage II and III GC cohorts, 11 and a previous report of a pan-cancer study using TCGA datasets also showed that TMIT III accounted for the smallest subtype except for a few specific entities such as glioblastoma, chromophobe type renal cell carcinoma, and pheochromocytoma. 10 One reason for this could be the rarity of intrinsic oncogenic induction of PD-L1, also suggesting that TMIT III might have unique genetic profile. In this study, though only six TMIT III samples were subjected to targeted sequencing, we found that this group revealed some characteristic features. The most notable finding was the enrichment of mutations in PIK3CA, MTOR, and RICTOR. MTOR and RICTOR encode the TMIT IV did not show a distinguishable somatic mutation profile by itself. However, TMIT IV and TMIT I, the CD8 High groups, were enriched with mutations of BRCA2 and FLT4. BRCA2 is well-known for its role in the repair of double stranded DNA breaks via homologous recombination (HR), and is also one of the actionable genes in GCs
31
; defective BRCA2 implies a favorable response to platinum-based chemotherapy 32 and poly(ADP-ribose) polymerase inhibitors. 33 The association between BRCA2 mutation and TMIT I/IV, the highly inflamed TME groups, suggests that these subgroups of GC would be the good candidates for such treatment strategies. FLT4, also known as vascular endothelial growth factor receptor 3, is allegedly engaged in the angiogenesis pathway, and in vitro studies using GC cell lines has proved that the inhibition of this molecule results in reduced cell migration, further suggesting the close interaction of TMIT I/IV with surrounding microenvironment. 34 We found TMIT-specific gene amplification by copy number analysis using targeted sequencing results. The most notable finding was the amplification of the FGFR2 gene; FGFR2 amplification is observed in 3%-9% of GCs and it is reported to be a poor prognostic indicator 35 as well as predictive factor for favorable response to pan-FGFR inhibitor therapy. 36 This genetic alteration with therapeutic implication was found exclusively within TMIT IV, in which the specific somatic mutational profile was not conspicuous. IGF2 copy number gain was observed in one TMIT II case; IGF2 acts by binding IGF1-receptor (IGF1R) as well as IGF2-receptor, and considering that IGF1R and its downstream signaling molecules were recently reported to have therapeutic implications in socalled "mesenchymal phenotype (MP)" GCs, 37 a possible relationship between TMIT II and MP subtype should be further characterized.
Regarding these various TMIT-specific somatic mutations and CNVs, further studies would be required to clarify the functional effects of genetic alterations and their interactions with tumor immune microenvironment.
We also observed that EBV + GCs were significantly enriched with PIK3CA mutations, as reported by the TCGA group and subsequent studies. 38 In addition, CTNNB1 mutations were enriched in EBV + GCs, consistent with previous reports 39 : among the seven CTNNB1 mutated cases in the present cohort, five of them were found in EBV + GCs.
MSI-H GCs were also enriched with PIK3CA mutations; however, none of the seven patients harbored TP53 mutations, possibly reflecting the distinct mutation profiles of MSI-H GCs and GCs with chromosomal instability, represented by TP53 mutations. Recent studies in colorectal adenocarcinoma and endometrial adenocarcinoma suggested that RNF43 plays a role in the carcinogenesis of MSI-H cancers. 40 The finding that three out of seven RNF43 mutated cases were MSI-H GCs in this study implies the potential association between FIGURE 4 Clustering analysis based on somatic mutation profiles. A, Fuzzy clustering method was adapted to classify stage II and III GCs solely based on the number of somatic mutations per case. As a result, two clusters were discriminated. Cluster 1 shows a markedly larger number of somatic mutations compared to cluster 2, with some exceptions, including TP53, in which case the mutations were more frequently observed in cluster 2. B, Overall survival (OS) according to the cluster model was analyzed and plotted, and cluster 2 showed relatively shorter survival with marginal statistical significance RNF43 and the MSI status in GCs as well. In addition, ATR mutations are known to be exclusively present in MSI-H endometrial adenocarcinomas, 41 and enriched ATR mutations in MSI-H GCs in this study also suggests the important role of ATR in microsatellite instability.
We made efforts to figure out the association between the two remaining molecular subtypes of GCs-genomically stable (GS) and chromosomal instability (CIN) GCs-and TMIT classification, based on the mutational data derived from this study. The mutations of CDH1
gene-the hallmark gene of GS type GCs-were relatively rare among TMIT I GCs compared to others (I vs. II/III/IV, P = .025), therefore we were able to cautiously raise a hypothesis that GS types would rather be associated with non-TMIT I GCs. However, the frequency of TP53 mutation did not show any preponderance toward specific TMIT, thus assuming any association between CIN and TMIT at this moment would require more profound evidence. In addition, rather than determining molecular classification of GC solely based on single genetic alterations, further studies based on additional genetic data including gene expression data and more delicate approach including signature or pathway analysis would be required.
Based on the novel findings derived from the targeted sequencing data, we performed fuzzy clustering analysis 42 GCs. For a classification scheme of a disease to be clinically meaningful, it is crucial that the classification method should provide prognostic information as well as clinicopathological associations. An example is our previous report on the prognostic implications of TMIT classification. Therefore, although cluster modeling succeeded in confirming the higher mutation frequencies of TMIT I and MSI-H GCs, we conclude that TMIT is still a more useful classification, which is much easier to adapt compared to targeted sequencing, and provides more relevant clinical information and better prognostic performance.
The evidence emphasizing the TMB as the predictive marker of favorable response to immunotherapy is growing, 46, 47 and studies have suggested that TMIT classification, oncogenic viral infection, and MSI status are important factors that harbor significant relationship with TMB. 46, 48, 49 In line with these previous results, the calculation of TMB based on our sequencing data showed that TMIT I was estimated to have the largest TMB among four TMIT groups, suggesting that GC patients with TMIT I phenotype may have a good chance to show favorable clinical outcome by immunotherapeutic agents. 48 In addition, our analysis also confirmed the higher TMB of EBV + cases, and showed strikingly higher TMB in MSI-H GCs, re-emphasizing the clinicopathologic importance of these two distinct subtypes of GC in the era of immunotherapy.
This study had the limitation of a lack of matched normal samples.
To efficiently rule out the possible germline variants, we applied the validated and widely-used NGS pipeline for data analysis [12] [13] [14] [15] [16] [17] and used filtering guidelines strictly based on previous studies. 18, 19 Though the samples in this study were entirely composed of FFPE tissue, we specifically selected samples with short cold ischemic time; a recent study showed that the sequencing results of FFPE are compatible with the results of fresh frozen samples, given that the appropriate analytic methods are undertaken. 50 The TMB calculation in this study was based on limited region of genome-spanning the exonal regions of 170 cancer related genes-therefore further validation of current in-house developed pipeline is required.
To the best of our knowledge, this is the first study to analyze molecular genetic characteristics based on TMIT, which considers both tumor cell characteristics and TME. Most importantly, the subgroup mutation analysis according to each TMIT revealed underrepresented genetic alterations, thereby unveiling more insights into GC biology. By introducing cluster modeling, we also confirmed the higher mutation frequency of TMIT I, EBV, and MSI-H GCs, solely based on the targeted sequencing data itself, providing clues for biological linkage between GC genetics and TME.
